MNTA News and Press, Momenta Pharmaceuticals Inc. From 08/03/20

CAMBRIDGE, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that it will release its financial results...

The FDA has signed off on Rare Pediatric Disease designation for Momenta Pharmaceuticals' (NASDAQ: MNTA ) nipocalimab for the prevention of hemolytic disease of the fetus and newborn, a rare disorder in babies in which red blood cells break down at a fast rate, a condition called erythr...

CAMBRIDGE, Mass., July 28, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) today announced that its novel drug candidate, nipocalimab, has received rare pediatric disease designation from the U.S. Food and Drug Administration (FDA) for the prevention of hemolytic d...

Quick Take Annexon ( ANNX ) intends to raise $150 million from the sale of its common stock in an IPO, according to an amended registration statement . The company is developing treatments for autoimmune and neurodegenerative conditions. ANNX is pursuing multiple treatment programs with...

Quick Take Annexon ( ANNX ) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement. The company is a clinical stage biopharma developing antibodies for treating autoimmune and neurodegenerative diseases. ANNX is targeting a number of s...

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. Biotech ETFs allow market participants to invest in multiple biotech companies via one vehicle. The life science sector certainly holds a risk factor, and ETFs are a good way to enter th...

Shares of Momenta Pharmaceuticals (NASDAQ: MNTA) were up by about 15% at 2:04 p.m. EDT Monday after the biotech released positive results from its phase 2 clinical trial of nipocalimab as a treatment for generalized myasthenia gravis. Generalized myasthenia gravis is a chronic autoimmune ...

Momenta Pharmaceuticals ( MNTA +0.9% ) announces positive topline results from a proof-of-concept Phase 2 clinical trial, Vivacity-MG , evaluating nipocalimab (formerly M281) in patients with generalized myasthenia gravis (MG), a disorder characterized by weakness and rapid fatigue of s...

- Trial met primary endpoint with a strong relationship between Immunoglobulin G (IgG) reduction and MG-ADL clinical benefit (p<0.0001) -       - Nipocalimab induced a rapid and durable response in the myasthenia gravis activities of daily living score (MG-ADL) ...

Market Pulse The question of whether it's a new bull market rally or just an intermittent bear market rally doomed to end later this year will most likely be decided late in the third quarter or during the fourth quarter when enough evidence on the durability of the recovery pace is forthcom...